161
Participants
Start Date
November 7, 2016
Primary Completion Date
November 4, 2021
Study Completion Date
November 4, 2021
Glesatinib
Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
Sitravatinib
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Mocetinostat
Mocetinostat is an HDAC inhibitor.
Nivolumab
nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Fox Chase Cancer Center, Philadelphia
Virginia Cancer Specialist, Fairfax
Vanderbilt University, Nashville
Baptist Health, Louisville
Ohio State University Comprehensive Cancer Center, Columbus
University Hospitals Cleveland Medical Center, Cleveland
Oncology Hematology Care-Blue Ash, Cincinnati
Henry Ford Hospital, Detroit
University of Wisconsin, Madison
Minnesota Oncology Hematology, P.A., Minneapolis
University of Minnesota Masonic Cancer Center, Minneapolis
Saint Francis Cancer Treatment Center, Grand Island
USOR - Texas Oncology - Denison Cancer Center, Denison
Texas Oncology - Tyler, Tyler
MD Anderson Cancer Center, Houston
Texas Oncology - South Austin, Austin
Rocky Mountain Cancer Centers - Denver - Midtown, Denver
Yuma Regional Medical Center, Yuma
Beverly Hills Cancer Center, Beverly Hills
City of Hope National Medical Center, Duarte
University of California Los Angeles - Torrance - Community Cancer Care, Santa Clarita
University of California San Diego, La Jolla
University of California San Francisco Comprehensive Cancer Center, San Francisco
Northwest Cancer Specialists, P.C., Tualatin
Hematology Oncology Associates - Barnett Office, Medford
Lead Sponsor
Mirati Therapeutics Inc.
INDUSTRY